Dtsch Med Wochenschr 2007; 132(25/26): 1373-1375
DOI: 10.1055/s-2007-982037
Klinischer Fortschritt | Commentary

© Georg Thieme Verlag KG Stuttgart · New York

Nephrologie 2007

Nephrology 2007C. Hugo1
  • 1Medizinische Klinik 4, Universität Erlangen-Nürnberg
Further Information

Publication History

eingereicht: 21.5.2007

akzeptiert: 24.5.2007

Publication Date:
15 June 2007 (online)

Was ist neu?

  • Zystennieren: Endlich Therapiemöglichkeiten?

  • Nephrogene systemische Fibrose: Zusammenhang mit Gadolinium?

Literatur

  • 1 Biance S, Bigazzi R, Campese V M. Long term effects of spironolacton on proteinuria and kidney function in patients with chronic kidney disease.  Kidney Int. 2006;  70 2116-2123
  • 2 Bukanov N O  et al. Long lasting arrest of murine cystic kidney disease with CDK inhibitor roscoviten.  Nature. 2006;  444 949-952
  • 3 Drueke T B, Locatelli F, Clyne N. et al . Normalization of hemoglobin level in patients with chronic kidney disease and anemia.  N Engl J Med. 2006;  355 2071-2084
  • 4 Epstein M, Williams G H. et al . Selective aldosteron blockade with eplerenone reduces albuminuria in patients with Type 2 diabetes.  Clin J Am Soc Nephrol. 2006;  1 940-951
  • 5 Grobner T. Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?.  Nephrol Dial Transplant. 2006;  21 1104-1108
  • 6 Hoste E A, Clermont G. et al . RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill patients: a cohort analysis.  Crit Care. 2006;  10 R73
  • 7 Liu K D, Himmelfarb J, Paganini E. et al . Timing of initiation of dialysis in critically ill patients with acute kidney injury.  Clin J Soc Am Nephrol. 2006;  1 915-919
  • 8 Marckmann P, Skov L, Rossen K. et al . Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging.  J Am Soc Nephrol. 2006;  17 2359-2362
  • 9 Marenzi G, Assanelli F, Marana I. et al . N-acetylcysteine and contrast-induced nephropathy in primary angioplasty.  N Engl J Med. 2006;  354 2773-2782
  • 10 Rocco M V, Frankenfield D L, Hopson S D, McClellan W M. Relationship between clinical performance measures and outcomes among patients receiving long term hemodialysis.  Ann Int Med. 2006;  145 512-519
  • 11 Singh A K, Szczech L, Tang K L. et al . Correction of anemia with epoetin alfa in chronic kidney disease.  N Engl J Med. 2006;  355 2085-2098
  • 12 Uchino S. et al . An assessment of the RIFLE criteria for acute renal failure in hospitalized patients.  Crit Care Med. 2006;  34 1913-1917
  • 13 Vinsonneau C, Camus C. et al . Continuous venovenous haemodiafiltration versus intermittent haemodialysis for acute renal failure in patients with multiple-organ dysfunction syndrome.  Lancet. 2006;  368 379-385
  • 14 Wattanakit K, Coresh . et al . Cardiovascular risk among adults with chronic kidney disease, with or without prior myocardial infarction.  J Am Coll Cardiol. 2006;  48 1183-1189
  • 15 Wattanakit K. et al . Kidney function and risk of peripheral arterial disease: Results from the atherosclerosis risk in community (ARIC) studies.  J Am Soc Nephrol. 2007;  18 629-636

Prof. Dr. med. Christian Hugo

Medizinische Klinik 4, Universität Erlangen-Nürnberg

Krankenhausstraße 12

91054 Erlangen

Phone: 09131/8536028

Fax: 09131/8539209

Email: christian.hugo@rzmail.uni-erlangen.de

    >